(Guangzhou, China, July 29, 2022) Pluslife Biotech had attended their first Annual Scientific Meeting & Clinical Lab Expo, the 2022 AACC that held in Chicago, USA. In the 2022 AACC, Pluslife showcased the latest Point-of-Care technology that pointing the alternative future of Nucleic Acid Test.

Since newer variants of the SARS-CoV-2 Omicorn family, named BA.4 and BA.5 spreading rapidly through the globe and outcompeting the infectious speed of previous subvariants. As a result of Pluslife Biotech's recent validations to confirm its products' capability to the detection of the BA.4 and BA.5, both the SAR-CoV-2 Nucleic Acid Test Kit and the newest SARS-CoV-2/Influenza A/Influenza B Test Kit have obtained such ability to coop with these new dominant variants that are currently circulating around the world. The new combo test kit, SARS-CoV-2/Influenza A/Influenza B Test Kit is able to diagnose multiple targets quickly, achieve suitable treatment and epidemic control simultaneously in complicated circumstances. The SARS-CoV-2/Influenza A/Influenza B Test Kit has entered mass production and made its first appearance in this AACC exhibition.

During the instrument platforms showcases of the Pluslife Mini Dock Integrated Nucleic Acid Testing Device, had attracted constant attention to discover new ways to achieve more efficient clinical performance in every application scenarios.

Congratulation on Pluslife Biotech’s AACC debut in Chicago. Pluslife is proud to showcase its innovative rapid molecular diagnostics to all the visitors. In the future, Pluslife will continue its dedication to deliver high-standard products that ultimately benefiting human welfare as always